Prevalence of sexually transmitted infections in the pre-MDA and post-MDA surveys
| Post-MDA survey % (95% CI) | ||||
|---|---|---|---|---|
| Pre-MDA survey (n=296) % (95% CI) | Overall (n=298)* | Reported receiving treatment during MDA (n=142) | Reported not receiving treatment during MDA (n=152) | |
| Chlamydia trachomatis | n=60 20.3% (15.9% to 25.4%) | n=43 14.4% (10.6% to 18.9%) | n=16 11.3% (6.6% to 17.7%) | n=27 17.8% (12.0% to 24.8%) |
| Neisseria gonorrhoeae | n=15 5.1% (2.9% to 8.2%) | n=9 3.0% (1.4% to 5.7%) | n=7 4.9% (2.0% to 9.9%) | n=2 1.3% (0.16% to 4.7%) |
*Four participants in the post-MDA survey were not sure if they had received MDA or not.
MDA, mass drug administration.